Abstract Library

#4141 BRAF/MEK combination treatment in a patient with BRAF mutated neuroendocrine carcinoma

Introduction: Preclinical studies indicate that BRAF V600E mutation is a druggable target in neuroendocrine carcinomas (NEC). Indeed, there are a few case reports that describe clinical response from BRAF inhibitor treatment of colorectal NEC.

Conference:

Presenting Author: Zhang L

Authors: Falkman L, Zhang L, Welin S, Crona J,

Keywords: Neuroendocrine carcinoma, BRAF V600E, Dabrafenib, Trametinib,

#3810 A patient with BRAF V600E mutated colon-NEC showing response to BRAF- and MEK inhibitors

Introduction: Preclinical studies have reported that the BRAF V600E mutation is a druggable target in colorectal neuroendocrine carcinomas (NECs). At least one case report has presented clinical success in the treatment of colorectal NEC using a BRAF inhibitor.

Conference:

Presenting Author:

Authors: Falkman L, Sundin A, Crona J, Wallin G, Welin S,

Keywords: neuroendocrine carcinoma, BRAF V600E, dabrafenib, trametinib, colorectal nec,

#3724 Tackling drug activity and resistance mechanisms in neuroendocrine tumors treated with cabozantinib

Introduction: Neuroendocrine tumors (NETs) are highly vascularized malignancies and angiogenesis plays a relevant role in cell proliferation and survival. Nowadays, innovative therapies have amplified the paradigm treatment of NETs. Among the compounds with anti-vascular properties, cabozantinib (CAB) appeared promising.

Conference:

Presenting Author: Cella C

Authors: Cella C, Cazzoli R, Fazio N, de Petro G, Gaudenzi G,

Keywords: Neuroendocrine tumor, angiogenesis, zebrafish model, mouse model.,

#3647 Autologous ECM-composed scaffolds and zebrafish PDXs for individualized theragnostic in rare neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are a subgroup of poorly characterized rare tumors with challenging management. Identification of clinically useful biomarkers for treatment tailoring is urgently needed.

Conference:

Presenting Author: Liverani C

Authors: Calabrese C, Miserocchi G, Vanni S, Mercatali L, de Vita A,

Keywords: NGS, zebrafish, autologous scaffold, molecular determinants,

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,